Azmi Nabulsi
2022
In 2022, Azmi Nabulsi earned a total compensation of $2.8M as Chief Operating Officer at Phathom Pharmaceuticals, a 36% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $274,838 |
---|---|
Option Awards | $1,947,240 |
Salary | $525,000 |
Other | $15,375 |
Total | $2,762,453 |
Nabulsi received $1.9M in option awards, accounting for 70% of the total pay in 2022.
Nabulsi also received $274.8K in non-equity incentive plan, $525K in salary and $15.4K in other compensation.
Rankings
In 2022, Azmi Nabulsi's compensation ranked 1,326th out of 5,760 executives tracked by ExecPay. In other words, Nabulsi earned more than 77.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,326 out of 5,760 | 77th |
Division Manufacturing | 654 out of 3,136 | 79th |
Major group Chemicals And Allied Products | 242 out of 1,422 | 83rd |
Industry group Drugs | 221 out of 1,323 | 83rd |
Industry Pharmaceutical Preparations | 159 out of 969 | 84th |
Source: SEC filing on April 13, 2023.
Nabulsi's colleagues
We found two more compensation records of executives who worked with Azmi Nabulsi at Phathom Pharmaceuticals in 2022.
News
Phathom Pharmaceuticals CEO Terrie Curran's 2023 pay falls 32% to $3.4M
April 12, 2024
Phathom Pharmaceuticals CEO Terrie Curran's 2022 pay slips 20% to $5M
April 13, 2023
Phathom Pharmaceuticals CEO Terrie Curran's 2020 pay jumps 34% to $4.6M
April 6, 2021
Phathom Pharmaceuticals CEO Terrie Curran receives $3.5M in 2019
April 8, 2020